Female Infertility – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Female Infertility Market Outlook

Thelansis’s “Female Infertility Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Female Infertility treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Female Infertility Overview

Infertility is a medical condition characterized by the inability to establish a clinical pregnancy despite engaging in regular and unprotected sexual intercourse for 12 months or more. It can also refer to an individual's or a couple's reduced reproductive capacity. Symptoms of infertility can vary among individuals, and in some cases, women may experience pelvic pain, heavy or irregular menstrual periods, or unpredictable vaginal bleeding. Spontaneous conception is influenced by three major factors: the duration of unsuccessful attempts to conceive, the age of the female partner, and infertility resulting from medical conditions. Additional factors contributing to infertility include a decline in semen quality over time, exposure to endocrine-disrupting chemicals, and consanguinity. Secondary infertility, the inability to conceive after a successful pregnancy, is the most prevalent form of female infertility worldwide. It is particularly common in regions with high rates of unsafe abortions and inadequate maternity care, leading to post-abortion and postpartum infections. Furthermore, the decline in female fertility begins around 25-30, and the median age for the last birth is 40-41 years. Infertility treatments may involve addressing various factors contributing to infertility. These treatments include ovulation induction, intrauterine insemination (IUI), in vitro fertilization (IVF), surgical interventions, egg donation, and preimplantation genetic testing.

• According to the Centers for Disease Control and Prevention (CDC), approximately 10 percent of women aged 15-44 in the United States (equivalent to 6.1 million women) face difficulties achieving or maintaining a pregnancy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: